Latest Neurimmune News & Updates

See the latest news and media coverage for Neurimmune. We track all announcements, press releases, and industry mentions in real time, all in one place.

Neurimmune

Biopharmaceutical company pioneering amyloid-depleting antibody therapies

neurimmune.com

Headquarters: Zurich Schlieren, Switzerland
Founded year: 2006
Company type: Private company
Number of employees: 60–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Neurimmune

In short: Neurimmune secured $425M from selling cliramitug royalties to Royalty Pharma and expanded its amyloidosis partnership with AstraZeneca.

Company announcements

July 22 Neurimmune

Neurimmune sells cliramitug royalty stake to Royalty Pharma for $425M

The deal includes $125M upfront and milestone payments, providing non-dilutive funding for R&D pipeline.

June 26 Neurimmune

Neurimmune published cliramitug long-term follow-up data in Nature Medicine

The data showed dose-dependent amyloid depletion and improved cardiac biomarkers and function in ATTR-CM patients.

5 December 2025 Neurimmune

AL-S Pharma reports positive Phase 2 AP-101 results for ALS

Study met safety endpoints with prolonged survival, delayed ventilatory support, and functional stabilization. Plans advance for confirmatory Phase 3 study.

4 December 2025 Neurimmune

Neurimmune expands collaboration with AstraZeneca for NI009

Exclusive global license agreement targets lambda light chain fibrils in AL amyloidosis. Neurimmune receives upfront payment, up to $780 million milestones, and royalties.

Media coverage

July 22 Yahoo Finance

Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma

Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125...

July 21 StartupTicker

Neurimmune closes licensing deal of up to USD425 million

Cliramitug is an investigational human monoclonal antibody discovered by Neurimmune and designed to deplete amyloid deposits from affected hearts in patients with amyloid transthy...

February 11 Pharmaphorum

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the...

3 December 2025 PR Newswire

Neurimmune expands collaboration with AstraZeneca to develop and commercialize fibril depleter NI009 for AL amyloidosis

/PRNewswire/ -- Neurimmune today announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca...

Never miss news about Neurimmune

Track Neurimmune and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Neurimmune competitors & trending companies

Browse news for competitors to Neurimmune and other trending companies.